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BREAST CANCER IS A HETEROG-eneous disease composed of agrowing number of recog-nized biological subtypes. The
prognostic and etiologic importance of
this diversity is complicated by many
factors, including the observation that
differences in clinical outcomes often
correlate with race. Age-adjusted mor-
tality in the United States from breast
cancer in white women is 28.3 deaths
per 100 000 compared with 36.4 deaths
per 100 000 in African American wom-
en.1 This disparity is particularly pro-
nounced among women younger than
50 years, in whom mortality is 77%
higher among African American women
compared with white women (11.0 vs
6.3 deaths per 100 000). Breast cancer
in African American women has been
characterized by higher grade,2,3 later
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Context Gene expression analysis has identified several breast cancer subtypes, in-
cluding basal-like, human epidermal growth factor receptor-2 positive/estrogen re-
ceptor negative (HER2/ER–), luminal A, and luminal B.
Objectives To determine population-based distributions and clinical associations for
breast cancer subtypes.
Design, Setting, and Participants Immunohistochemical surrogates for each sub-
type were applied to 496 incident cases of invasive breast cancer from the Carolina
Breast Cancer Study (ascertained between May 1993 and December 1996), a population-
based, case-control study that oversampled premenopausal and African American
women. Subtype definitions were as follows: luminal A (ER and/or progesterone re-
ceptor positive [PR], HER2−), luminal B (ER and/or PR, HER2), basal-like (ER−,
PR−, HER2−, cytokeratin 5/6 positive, and/or HER1), HER2/ER− (ER−, PR−, and
HER2), and unclassified (negative for all 5 markers).
Main Outcome Measures We examined the prevalence of breast cancer sub-
types within racial and menopausal subsets and determined their associations with tu-
mor size, axillary nodal status, mitotic index, nuclear pleomorphism, combined grade,
p53 mutation status, and breast cancer–specific survival.
Results The basal-like breast cancer subtype was more prevalent among pre-
menopausal African American women (39%) compared with postmenopausal Afri-
can American women (14%) and non–African American women (16%) of any age
(P.001), whereas the luminal A subtype was less prevalent (36% vs 59% and
54%, respectively). The HER2/ER− subtype did not vary with race or menopausal
status (6%-9%). Compared with luminal A, basal-like tumors had more TP53
mutations (44% vs 15%, P.001), higher mitotic index (odds ratio [OR], 11.0;
95% confidence interval [CI], 5.6-21.7), more marked nuclear pleomorphism (OR,
9.7; 95% CI, 5.3-18.0), and higher combined grade (OR, 8.3; 95% CI, 4.4-15.6).
Breast cancer–specific survival differed by subtype (P.001), with shortest survival
among HER2/ER− and basal-like subtypes.
Conclusions Basal-like breast tumors occurred at a higher prevalence among pre-
menopausal African American patients compared with postmenopausal African
American and non–African American patients in this population-based study. A
higher prevalence of basal-like breast tumors and a lower prevalence of luminal A
tumors could contribute to the poor prognosis of young African American women
with breast cancer.
JAMA. 2006;295:2492-2502
stage at diagnosis,2,4 and worse sur-
vival even after controlling for stage at
diagnosis.4-6 The causes of this ob-
served survival difference are likely mul-
tifactorial and includesocioeconomic fac-
tors,4 differences in access to screening7
and treatment,6 as well as potential bio-
logical differences among the cancers
themselves.3,8,9 Biological differences
among breast cancers may reflect ge-
netic influences, differences in lifestyle,
or nutritional or environmental expo-
sures. In addition, studies that include
race as a characteristic must take into ac-
count that there is significant disagree-
ment as to how race is measured and in-
terpreted in medical research.10-12
Gene expression studies using DNA
microarrays have identified several dis-
tinct breast cancer subtypes13 based on
an intrinsic gene list that includes 496
genes that differentiate breast cancers
into separate groups based only on gene
expression patterns. These subtypes dif-
fer markedly in prognosis14-16 and in the
repertoire of therapeutic targets they ex-
press.17 The intrinsic subtypes include
2 main subtypes of estrogen receptor
(ER)–negative tumors (basal-like and
human epidermal growth factor recep-
tor-2 positive/ER− [HER2/ER−] sub-
type) and at least 2 types of ER tu-
mors (luminal A and luminal B).14,15
Basal-like tumors typically show low ex-
pression of HER2 and ER and exhibit
high expression of genes characteris-
tic of the basal epithelial cell layer, in-
cluding expression of cytokeratins 5, 6,
and 17.13 The HER2 (ie, gene ampli-
fied and/or highly overexpressed pro-
tein) tumors fall into at least 2 distinct
expression groups: those that are ER−
and typically cluster near the basal-
like tumors (HER2/ER− subtype), and
those that are ER (and may also be
progesterone receptor positive [PR])
and cluster with tumors of luminal cell
origins as part of the luminal B sub-
type.14,15 The luminal subtype A and B
tumors express ER, GATA3, and genes
regulated by both ER and GATA3.18,19
Compared with luminal B tumors, lu-
minal A tumors express higher levels
of ER and GATA3 and show more fa-
vorable patient outcomes,15 whereas lu-
minal B tumors more often express hu-
man epidermal growth factor receptor-1
(HER1), HER2, and/or cyclin E1.14,15
Previous expression studies exam-
ined breast cancer subtypes in small
data sets derived from frozen tumor
banks.14-16,20,21 The incidence of any of
these molecular subtypes in a large
population-based study and their rela-
tionship with demographic variables
have not been systematically evalu-
ated. The Carolina Breast Cancer Study
(CBCS) is a population-based, case-
control study of environmental and mo-
lecular determinants of breast cancer
risk.22 The CBCS is unique in that it
oversampled African American and pre-
menopausal women to allow better rep-
resentation of these 2 subpopulations,
making it well-suited for the examina-
tion of race- and age-related variables.
We used immunohistochemical (IHC)
surrogates to identify breast tumor in-
trinsic subtypes using formalin-fixed,
paraffin-embedded tumor blocks col-
lected for CBCS cases, and examined
associations between tumor subtypes
and race, menopausal status, tumor
characteristics, and survival.
METHODS
Definition of Breast Cancer
IHC Subtypes
Although breast cancer subtypes were
originally identified by gene expres-
sion analysis using DNA microarrays,
large-scale subtyping using gene ex-
pression profiling from formalin-
fixed, paraffin-embedded samples is not
currently feasible. For this reason, we
used IHC markers that had been pre-
viously verified against gene expres-
sion profiles to estimate the preva-
lence of the intrinsic subtypes in a large
population-based epidemiological study
of African American and white women.
The IHC profiles were developed pre-
viously by performing both microar-
ray analysis and IHC for ER, HER2,
HER1, and cytokeratin 5/6 on a single
series of breast cancers; in that way, we
identified combinations of these IHC
markers that best matched the gene ex-
pression patterns, and then validated
these IHC surrogates using a 930-case
tissue microarray from the University
of British Columbia.17 In that earlier
study, the IHC-based definitions were
luminal (ER and HER2−), HER2
subtype, and basal-like (ER−, HER2−,
cytokeratin 5/6, and/or HER1). We
updated these IHC-based definitions in
2 ways: first, we included PR, which is
another widely used breast tumor
marker, in the definition of luminal be-
cause PR is an ER-regulated gene ex-
pressed in most ER tumors and is as-
sociated with response to hormonal
therapy. Second, we recategorized
HER2 tumors into 2 groups based on
their ER status since HER2/ER− tu-
mors cluster separately from HER2/
ER tumors in hierarchical cluster-
ing analyses.14,15 In this way, we refined
the previous IHC profiles for the breast
cancer subtypes and created updated
IHC subtype definitions: basal-like
(ER−, PR−, HER2−, cytokeratin 5/6,
and/or HER1), HER2/ER− sub-
type (HER2, ER−, PR−), luminal A
(ER and/or PR, HER2−), and lumi-
nal B (ER and/or PR, HER2). This
definition for luminal B does not iden-
tify all luminal B tumors because only
30% to 50% are HER2. The other lu-
minal B tumors in this system would
be classified with luminal A tumors. Tu-
mors that were negative by IHC for all
5 markers (ER, PR, HER2, HER1, and
cytokeratin 5/6) were considered un-
classified. These refined IHC profiles are
seen in FIGURE 1. In support of the up-
dated profiles, the HER2 and ER tu-
mors (by gene expression) were found
mostly within the ER tumor dendro-
gram branch and within the luminal B
subtype, whereas the HER2 and ER−
tumors that represent the HER2/
ER− subtype gene expression pattern
were seen within a distant ER− tumor
dendrogram branch, which suggests
that these 2 groups are different.
Study Population
The CBCS is a population-based, case-
control study conducted in 24 coun-
ties of eastern and central North Caro-
lina.22 The goal of the present analysis
was to estimate the prevalence of breast
cancer subtypes in a population-based
sample of breast cancer cases, and to
examine correlations with clinico-
pathologic variables and patient sur-
vival. The analysis was based on breast
cancer cases ascertained between May
1993 and December 1996 (phase 1 of
the CBCS) and excluded controls.
Newly diagnosed (incident) cases of in-
vasive breast cancer in women be-
tween the ages of 20 and 74 years were
identified using a rapid ascertainment
system developed in collaboration with
the North Carolina Central Cancer Reg-
istry. Cases were selected by random-
ized recruitment with predetermined
probabilities to increase enrollment of
African American women and women
younger than 50 years so that these oth-
erwise underrepresented subpopula-
tions would represent approximately
50% of the study population. The sam-
pling strategy was intended to balance
the 4 patient groups (younger African
American, older African American,
younger non–African American, older
non–African American cases) so that
statistically valid comparisons could be
made for each of the 4 groups. To this
end, the schema sampled 100% of Af-
rican American cases younger than 50
years, 75% of African American cases
at least 50 years old, 67% of non–
African American cases younger than
age 50 years, and 20% of non–African
American cases at least 50 years old.22
Other than the oversampling of younger
and African American women by de-
sign, the CBCS population is represen-
tative of cases reported to the North
Carolina Central Cancer Registry in that
region of North Carolina during that
time, except for a slightly lower pro-
portion of African American cases
aged 40 to 59 years with later-stage dis-
ease (2.4% vs 10.2%, P=.03).2 Con-
tact rates in the CBCS were lowest
among younger women and African
American women, while participation
rates were lowest among older women
and African American women.23 Com-
pared with women who participated
in the CBCS, nonparticipants were
more likely to be of lower socioeco-
nomic status, to have a lower educa-
tional level, and to have a recent his-
tory of unemployment.23
The study procedures for recruit-
ment and enrollment were approved by
the institutional review board of the
University of North Carolina School of
Medicine, and all study participants
gave written informed consent.
Race was determined by self-
identification and for analysis was cat-
egorized as African American or non–
African American. Non–African
Figure 1. Immunohistochemical Identification of Breast Tumor Intrinsic Subtypes
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Luminal A Luminal B HER2+/ER-Microarray-Based Breast
Cancer Subtype15, 17
Basal-like
Normal Breast–like
ER+ and/or PR+,
  HER2-
ER+ and/or PR+,
  HER2+
ER-, PR-,
  HER2+
Immunohistochemical
Profile
ER-, PR-, HER2-,
  CK5/6+ and/or HER1+
Lower  Higher Median
5.6 4 2.8 2 1.4 1 1.4 2 2.8 4 5.6
Gene Expression
(Fold Difference Relative to Median Level of Expression Across All Samples)
The 115 patient/tumor sample dendrogram was taken from the hierarchical clustering analysis of the breast intrinsic gene list.15,17 Tissue samples in gray indicate un-
known subtype. The gene expression data for estrogen receptor (ER), human epidermal growth factor receptor-2 (HER2), CK5 (cytokeratin), and HER1 are shown with
red squares representing the highest average expression, black representing average gene expression, and green representing the lowest below average expression.
Gray indicates gene expression data not available. Note that PR (progesterone receptor) was not included in this gene expression analysis because it was not present
on these early generation microarrays. Below the gene expression data are the revised immunohistochemical (IHC) classification schema used in this study. PR was
added to the IHC profile since it is an ER-regulated gene expressed in most ER tumors.
American cases were predominantly
white but also included 14 women who
reported their race as Native Ameri-
can, Hispanic, Asian American, or mul-
tiracial. Information on race was
obtained since a primary goal of the
CBCS was to better understand breast
cancer in African American women.
Menopausal status was based on in-
person interview data. Sampling was
done according to age (since meno-
pausal status was not obtained until
interviews), but this did not affect the
results (presenting by menopausal sta-
tus rather than by age 50 and 50
years). Women younger than 50 years
who had undergone natural meno-
pause, bilateral oophorectomy, or irra-
diation to the ovaries were classified as
postmenopausal and were considered
together. In women aged 50 years or
older, menopausal status was assigned
based on cessation of menstruation.24
Centralized review of histology for all
tumors was conducted by a single
pathologist (J.G.),2 who was blinded
to patient demographics and other study
variables. Based on histology, tumors
were classified into 6 groups: A (inva-
sive ductal carcinomas not otherwise
specified, medullary, apocrine, neuro-
endocrine carcinomas), B (tubular,
mucinous, papillary carcinoma,
cribriform carcinomas), C (metaplas-
tic, anaplastic, undifferentiated high-
grade carcinomas), D (invasive lobular
carcinomas), E (mixed ductal and lobu-
lar carcinomas), and unknown (unable
to classify). Tumor size, lymph node sta-
tus, and American Joint Committee on
Cancer (AJCC,5thedition) stageatdiag-
nosis were abstracted from the medical
records. Nuclear grade, histologic grade,
and mitotic index were previously deter-
mined2 according to the Nottingham
modification of the Scarff-Bloom-
Richardsoncriteria.25 Highmitotic index
was defined as greater than 10 mitotic
figures per 10 high-power fields.
Estrogen receptor and PR status were
determined from medical records (80%)
or by IHC performed at the University
of North Carolina-Lineberger Compre-
hensive Cancer Center Immunohisto-
chemistry Core Facility in Chapel Hill.26
For the cases in which ER and PR status
was obtained from the medical record,
various clinical laboratories deter-
mined the results. About half used IHC
on paraffinized tissue with cutoffs for
receptor positivity from more than 0%
to more than 20%, and about half used
biochemical assays on frozen tissue with
cutoffs of 10 to 15 fmol/mg. For the
remaining tumors, IHC was performed
in the Core laboratory at the University
of North Carolina.26 Scoring for IHC was
adapted from the method of the the Uni-
versity of North Carolina Hospitals
Department of Pathology with 5% inva-
sive breast cancer nuclei-positive cells as
the cutoff value for ER or PR status. In a
10%randomsampleof23cases thatwere
ER and 24 cases that were ER− based
on medical records, comparison of the
medical recordIHCresultwithIHCdone
by the Core Laboratory at the Univer-
sity of North Carolina revealed a  sta-
tisticof0.62, indicatingsubstantialagree-
ment beyond chance27 with an overall
concordance of 81%. The HER2 status
was determined using the CB11 anti-
body (Biogenex, San Ramon, Calif) as
previouslydefined.28 HER2-positivitywas
defined as membrane or membrane plus
cytoplasmicstainingwithweakorgreater
intensity in at least 10% of tumor cells.
On a subset of 184 patients, a compari-
sonof2 independentscorersof theHER2
IHCassay,whowereblindedto theother
clinical variables, yielded a  statistic of
0.58, indicating moderate agreement
beyond chance27 with an overall concor-
dance of 82%. Staining for HER1 was
categorized using a 0 to 3 scoring sys-
tem,17 andourassignmentofHER1posi-
tivity was defined as any HER1 staining.
Cytokeratin 5/6 was scored positive if
any cytoplasmic and/or membranous
staining was seen.29
ATP53mutational analysis was per-
formed at the University of North Caro-
lina-Lineberger Comprehensive Can-
cer Center Molecular Epidemiology
Core Facility using single-strand con-
formational polymorphism analysis
with direct sequencing of positive
results aspreviouslydescribed.30 Screen-
ing for germline mutations in BRCA1
was accomplished using multiplex
single-strand conformation analysis as
previously described on the first 211
cases in phase 1 of the CBCS.31
Survival Data
The National Death Index provided vital
statusonCBCScases asofMay11,2004.
These data were derived from death
certificates and included all causes of
death for overall survival and disease-
specific cause of death for breast cancer–
specific survival. In 1 large epidemio-
logical study, the sensitivity of the
National Death Index search was 98%
and specificity was approximately 100%
for breast cancer.32 Breast cancer-
specific survival was determined by the
International Classification of Diseases
(ICD) breast cancer codes 174.9 (ICD-9)
or C50.9 (ICD-10) as the underlying
cause of death on the death certificate.
Statistical Analysis
To account for the sampling strategy
that systematically overrepresented cer-
tain patient groups (eg, younger, Afri-
can American), analyses are presented
stratified by the 4 patient groups. Dif-
ferences between breast cancer sub-
types with regard to clinicopathologic
characteristics were examined using
1-way analysis of variance (ANOVA) for
age, and 2 tests for the remaining vari-
ables. The Fisher exact test was used
when expected cell counts were less
than 5 using the Monte Carlo method
as implemented in SAS.33 Odds ratios
(ORs) and 95% confidence intervals
(CIs) were calculated to estimate mag-
nitude and precision of association
among breast cancer cases. Odds ra-
tios represent prevalence and were cal-
culated using logistic regression as
implemented in SAS version 8.0 (SAS
Institute Inc, Cary, NC). P values were
similar when prevalence ratios were
used as the measure of association, but
several models did not converge. The
reported P values reflect the  coeffi-
cient in the relevant logistic model.
Variables were chosen based on clini-
cal interest, and included age, race, and
stage at diagnosis. Because of collinear-
ity with stage, lymph node status was
not included with stage in logistic mod-
els. To test for overfitting, we per-
formed the Hosmer-Lemeshow good-
ness-of-fit test,34 which did not reveal
significant evidence for lack of fit. Like-
lihood ratio tests for interaction were
conducted by comparing models with
main effects to models with main ef-
fects plus an interaction term. P val-
ues were not corrected for multiple
comparisons since the variables exam-
ined (clinicopathologic variables, defi-
nitions of breast cancer subtypes) were
not independent and thus do not rep-
resent separate statistical tests. Sur-
vival curves were generated using the
Kaplan-Meier method,35 and the log-
rank test36 was used to compare mean
survival across the IHC subtypes. To
confirm that the assumptions of the log-
rank test were fulfilled,36 we deter-
mined that censoring due to non–
breast cancer causes of death was
unrelated to breast cancer subtype
(P= .55), and the proportion of pa-
tients in each of the breast cancer sub-
types did not differ across the years of
enrollment in the study (P=.41). Cen-
soring did not differ according to year
of enrollment in the study for 5-year
breast cancer–specific survival (P=.73)
or overall survival (P=.33). Date and
cause of death were obtained from the
National Death Index and were thus as-
signed without knowledge of breast
cancer subtype.
As a further test for differences in sur-
vival among breast cancer subgroups,
we performed univariate Cox regres-
sion to estimate hazard ratios for basal-
like breast cancer vs luminal A, and
for HER2/ER− breast cancer vs lumi-
nal A.37 Power calculations were per-
formed using a computer program
developed by Dupont and Plummer,38
and concluded that power was very
good (70%-80%) or excellent (80%)
for the majority of comparisons in this
analysis. Statistical analysis was per-
formed by C.K.T. under the supervi-
sion of R.C.M.
RESULTS
Patient Population
A total of 1153 incident cases of inva-
sive breast cancer were identified in
phase 1 of the CBCS. Successful con-
tact was obtained in 861 cases (75%),
and of these 807 (94%) had tumor
blocks or tissue sections for central-
ized review and IHC. Of the 807 cases,
496 (61%) had both adequate tumor
and interpretable IHC data for ER, PR,
HER2, cytokeratin 5/6, and HER1,
which was a requirement for inclu-
sion in the subtype analysis. These cases
included 196 African American and 300
non–African American women. Com-
parison of these 496 cases included
those with the 365 excluded cases (on
whom we did not have either ad-
equate tumor tissue or complete IHC
data) revealed the following differ-
ences: the included cases were more
likely to be stage II (51% vs 39%) and
less likely to be stage I (39% vs 48%),
with little difference seen in stage III
(8% vs 10%) or stage IV (3% vs 4%) per-
centages. The included cases also were
more likely to have tumors with high
mitotic indices (46% vs 34%, P.001).
These differences likely reflected the
fact that tumor blocks from patients
with smaller tumors were either un-
available or had insufficient tissue for
subtype analysis. There were no differ-
ences between the included and ex-
cluded cases in age, race, menopausal
status, lymph node status, nuclear
grade, histologic grade, or survival.
IHC Subtype Associations With
Clinical and Demographic Data
Characteristics of the 496 CBCS cases
with IHC data, overall and according
to IHC subtypes, are presented in
TABLE 1. The IHC subtypes differed
significantly by age (P.001), race
(P=.03), menopausal status (P=.008),
combined race and menopausal status
(P.001), axillary lymph node status
at time of diagnosis (P=.04), histol-
ogy group (P.001), nuclear grade
(P.001), histologic grade (P.001),
and mitotic index (P. 001). Patients
with luminal A and B tumors were older
than the other patients, and patients
with the HER2/ER− subtype had the
highest prevalence of positive lymph
nodes. Patients with basal-like tumors
were more likely to be African Ameri-
can, premenopausal, and to have tu-
mors with high nuclear grade, high his-
tologic grade, and high mitotic index.
Basal-like tumors also showed the high-
est prevalence of unfavorable histolo-
gies (group C: metaplastic, anaplastic,
and undifferentiated high-grade
carcinomas).
In the overall study population, the
prevalence of the basal-like subtype was
20% (100 cases total). The prevalence
of basal-like breast cancer was signifi-
cantly higher in African American
breast cancer cases, comprising 52 of
196 African American women (26%) vs
48 of 300 non–African American cases
(16%) (Table 1). Basal-like tumors were
also more frequent in premenopausal
cases, comprising 64 of 261 (24%) vs
36 of 235 (15%) postmenopausal cases.
These prevalence estimates should be
interpreted with caution, because they
do not reflect the sampling probabili-
ties used to define eligible cases in the
CBCS. To account for the sampling
strategy, separate estimates were de-
rived for each of the 4 patient groups
defined a priori (TABLE 2). The high
prevalence of basal-like tumors in Af-
rican American women was mostly seen
in premenopausal women, in whom the
prevalence was 39%. The prevalence of
basal-like breast cancer in premeno-
pausal African American women was
significantly elevated compared with
postmenopausal African American
(14%) or non–African American
women (16%) of any age (P.001)
(Table 2). The difference in preva-
lence of basal-like breast cancer be-
tween premenopausal and postmeno-
pausal cases was statistically significant
among African American cases
(P .001), but not among non–
African American cases (P=.94). The
luminal A subtype, conversely, was less
frequent among premenopausal Afri-
can American women (36%) com-
pared with postmenopausal African
American (59%) or non–African Ameri-
can (54%) women. The higher preva-
lence of basal-like breast cancers in
younger African American patients was
maintained when we stratified on stage
at diagnosis. For example, among cases
Table 1. Characteristics of Carolina Breast Cancer Study Patients With Immunohistochemical Marker Data
Characteristic
No. (%)
P Value*
All Cases
(N = 496)
Basal-like
(n = 100)
HER2/ER−
(n = 33)
Luminal A
(n = 255)
Luminal B
(n = 77)
Unclassified
(n = 31)
Age, mean (SD), y 50 (12) 46 (10) 47 (9) 52 (12) 50 (12) 45 (11) .001
Race
African American 196 (40) 52 (52) 16 (48) 93 (36) 25 (32) 10 (32)
.03
Non–African American 300 (60) 48 (48) 17 (52) 162 (64) 52 (68) 21 (68)
Menopausal status
Premenopausal 261 (53) 64 (64) 18 (55) 118 (46) 39 (51) 22 (71)
.008
Postmenopausal 235 (47) 36 (36) 15 (45) 137 (54) 38 (49) 9 (29)
AJCC stage
I 184 (39) 23 (24) 9 (28) 108 (44) 29 (39) 15 (48)
II 242 (51) 59 (62) 17 (53) 114 (47) 40 (54) 12 (39)
.06
III 36 (8) 8 (8) 4 (13) 17 (7) 4 (5) 3 (10)
IV 13 (3) 5 (5) 2 (6) 4 (2) 1 (1) 1 (3)
Missing 21 5 1 12 3 0
Lymph node status
Positive 189 (39) 41 (41) 18 (56) 86 (34) 35 (47) 9 (29)
.04
Negative 298 (61) 58 (59) 14 (44) 165 (66) 39 (53) 22 (71)
Missing 9 1 1 4 3 0
ER status
Positive 295 (60) 0 0 220 (86) 75 (97) 0
.001
Negative 201 (40) 100 (100) 33 (100) 35 (14) 2 (3) 31 (100)
PR status
Positive 280 (56) 0 0 214 (84) 66 (86) 0
.001
Negative 216 (44) 100 (100) 33 (100) 41 (16) 11 (14) 31 (100)
Combined ER-PR status
ER/PR 243 (49) 0 0 179 (70) 64 (83) 0
ER/PR− 52 (11) 0 0 41 (16) 11 (14) 0
.001†
ER−/PR 37 (7) 0 0 35 (14) 2 (3) 0
ER−/PR− 164 (33) 100 (100) 33 (100) 0 0 31 (100)
HER2 immunohistochemistry
Positive 110 (22) 0 33 (100) 0 77 (100) 0
.001
Negative 386 (78) 100 (100) 0 255 (100) 0 31 (100)
Histology group‡
A 375 (76) 84 (84) 31 (94) 178 (70) 61 (79) 21 (68)
B 18 (4) 0 0 15 (6) 1 (1) 2 (7)
C 20 (4) 10 (10) 0 8 (3) 1 (1) 1 (3) .001†
D 38 (8) 0 0 31 (12) 5 (7) 2 (7)
E 45 (9) 6 (6) 2 (6) 23 (9) 9 (12) 5 (16)
Unknown 0 0 0 0 0 0
Nuclear grade
Marked pleomorphism 212 (43) 80 (80) 25 (76) 66 (26) 21 (27) 20 (65)
Slight/moderate 283 (57) 19 (20) 8 (24) 189 (74) 56 (73) 11 (35)
.001
Missing 1 1 0 0 0 0
Histologic grade
Poorly differentiated 321 (65) 81 (82) 23 (70) 149 (58) 43 (56) 25 (81)
Well-/moderately differentiated 174 (35) 18 (18) 10 (30) 106 (42) 34 (44) 6 (19)
.001
Missing 1 1 0 0 0 0
Combined grade (Nottingham)
I 121 (25) 2 (2) 2 (6) 91 (36) 20 (26) 6 (19)
II 144 (29) 14 (14) 6 (19) 85 (33) 33 (43) 6 (19) .001†
III 227 (46) 82 (84) 24 (75) 78 (31) 24 (31) 19 (62)
Missing 4 2 1 1 0 0
Mitotic index
High, 10 per 10 hpf 226 (46) 85 (87) 22 (69) 78 (31) 25 (32) 16 (52)
Low, 10 per 10 hpf 267 (54) 13 (13) 10 (31) 177 (69) 52 (68) 15 (48)
.001
Missing 3 2 1 0 0 0
Abbreviations: AJCC, American Joint Committee on Cancer; ER, estrogen receptor; hpf, high-power field; HER2, human epidermal growth factor receptor-2; PR, progesterone
receptor.
*Comparing 5 subgroups (basal-like, HER2/ER−, luminal A, luminal B, unclassified) using analysis of variance to test for differences in means, and 2 or Fisher exact test for the
remaining characteristics.
†Fisher exact test.
‡Group A: invasive ductal carcinomas not otherwise specified, medullary, apocrine, neuroendocrine carcinomas; B: tubular, mucinous, papillary carcinoma, cribriform carcinomas;
C: metaplastic, anaplastic, undifferentiated high-grade carcinomas; D: invasive lobular carcinomas; E: mixed ductal and lobular carcinomas; unknown: unable to classify.
with stage I disease, the prevalence of
basal-like breast cancer was 40% in pre-
menopausal African American women,
6% in postmenopausal African Ameri-
can women, 10% in premenopausal
non–African American women, and 8%
in postmenopausal non–African Ameri-
can women (P=.001). This difference
by race and menopausal status was not
seen in the other ER− subtype (HER2/
ER−), which also was associated with
high grade (Table 1).
Odds ratios for the association of
breast cancer subtypes with lymph node
status, histologic grade, and mitotic in-
dex are presented in TABLE 3, with the
luminal A subtype (the most common
IHC subtype representing 51% of the
cases) serving as the referent group.
Odds ratios were adjusted for age, stage,
and race. Compared with the luminal A
subtype, patients with basal-like tu-
mors were 2.1 times more likely to be
African American (P= .004). Likeli-
hood ratio tests showed a significant
interaction between race and meno-
pausal status for developing the
basal-like subtype (P= .02), but not
HER2/ER− (P = .49), luminal B
(P=.62), or unclassified tumors (P=.58)
compared with luminal A. In compari-
son with luminal A tumors and after ad-
justment for age, race, and stage, the
basal-like subtype was 11 times more
likely to have high mitotic index
(P.001), 9.7 times more likely to have
high nuclear grade (P.001), and 2.5
times more likely to have high histo-
logic grade (P=.003). The basal-like sub-
type was not associated with the pres-
ence of positive axillary lymph nodes at
the time of diagnosis (P=.53), whereas
both HER2 subtypes (HER2/ER−
and luminal B) were significantly more
likely to have positive lymph nodes at
presentation (P=.04). Notably, a strong
association with high histologic, nuclear,
and mitotic grade was seen for both sub-
types of ER− tumors, namely the basal-
like and HER2/ER− tumors. How-
ever, the HER2/ER− subtype was not
significantly associated with race or
menopausal status.
The TP53 sequence-based mutation
analysis was performed on 330 of the
496 IHC classified breast cancer cases,
of which 84 (25%) had TP53 muta-
tions. The presence of TP53 muta-
tions differed significantly with IHC
subtype: 44% (28 of 63) of basal-like
tumors and 43% (10 of 23) of HER2/
ER− subtype tumors contained TP53
mutations, whereas only 23% (12 of 52)
of luminal B and 15% (25 of 175) of lu-
minal A were mutation-positive
(P.001). These findings were in agree-
ment with previous comparisons of the
breast tumor intrinsic subtypes and
TP53 mutation status14 as well as pre-
vious demonstration of a high propor-
tion of p53-mutant tumors in BRCA1
and cytokeratin 5/6–positive tumors.39,40
A subset of CBCS patients were
screened for BRCA1 germline muta-
tions.31 Of the 496 cases assayed, 211
were screened for mutations in BRCA1,
with 4 carriers and 1 variant of un-
Table 2. Prevalence of Breast Cancer Subtypes According to Race and Menopausal Status
Tumor
Status
All
Cases
No. (%)
African American* Non–African American†
Premenopausal
(n = 97)
Postmenopausal
(n = 99)
Premenopausal
(n = 164)
Postmenopausal
(n = 136)
Basal-like 100 38 (39) 14 (14) 26 (16) 22 (16)
HER2/ER− 33 9 (9) 7 (7) 9 (6) 8 (6)
Luminal A 255 35 (36) 58 (59) 83 (51) 79 (58)
Luminal B 77 9 (9) 16 (16) 30 (18) 22 (16)
Unclassified 31 6 (6) 4 (4) 16 (10) 5 (4)
*P.001, 2 test for basal-like vs other tumor types in premenopausal vs postmenopausal African American women.
†P = .94, 2 test for basal-like vs other tumor types in premenopausal vs postmenopausal non–African American women.
Table 3. Adjusted Odds Ratios for Patient and Tumor Characteristics by Breast Cancer Subtype*
Characteristic
Basal-like
(n = 100)
HER2/ER−
(n = 33)
Luminal B
(n = 77)
Unclassified
(n = 31)
OR (95% CI)
P
Value OR (95% CI)
P
Value OR (95% CI)
P
Value OR (95% CI)
P
Value
African American vs non–African American† 2.1 (1.3-3.4) .004 1.8 (0.8-3.8) .13 0.9 (0.5-1.5) .63 0.9 (0.4-2.1) .86
Premenopausal vs postmenopausal‡ 0.9 (0.4-1.9) .74 0.5 (0.2-1.5) .21 0.9 (0.4-2.2) .83 1.4 (0.4-6.0) .61
Stage III-IV vs I-II§ 1.4 (0.6-2.9) .41 2.1 (0.8-5.7) .16 0.8 (0.3-2.1) .58 1.3 (0.4-4.3) .62
Lymph node–positive vs negative§ 1.2 (0.7-1.9) .53 2.2 (1.0-4.7) .04 1.7 (1.0-2.9) .05 0.7 (0.3-1.7) .45
Nuclear grade: marked pleomorphism vs
slight/moderate‡
9.7 (5.3-18.0) .001 6.8 (2.8-16.3) .001 1.0 (0.5-1.8) .92 4.6 (2.0-10.4) .001
Histologic grade: poorly differentiated vs
well-/moderately‡
2.5 (1.4-4.6) .003 1.2 (0.5-2.7) .70 0.9 (0.5-1.5) .67 2.6 (1.0-6.8) .05
Combined grade (Nottingham) III vs III‡ 8.3 (4.4-15.6) .001 6.2 (2.4-16.0) .001 1.0 (0.5-1.7) .87 3.4 (1.5-7.9) .004
Mitotic index 10 vs 10 per 10 hpf‡ 11.0 (5.6-21.7) .001 4.3 (1.8-10.5) .001 1.0 (0.6-1.8) .95 2.3 (1.0-5.3) .04
Abbreviations: CI, confidence interval; hpf, high-power field; OR, odds ratio.
*The luminal A (ER and/or progesterone receptor positive, HER2−) subtype acts as the referent group.
†Adjusted for age (11-level ordinal variable) and stage (I, II, IIIIV).
‡Adjusted for age, race, and stage.
§Adjusted for age and race.
known effects being identified. The
BRCA1 mutation carriers comprised
1 luminal A tumor, 1 unclassified
tumor, and 2 basal-like tumors. Al-
though these numbers were very
small, the data were consistent with
earlier findings that most BRCA1
mutant tumors show the basal-like
phenotype15,41,42 and that most BRCA1
mutant tumors do not show HER2 posi-
tivity.43
Survival by IHC Subtype
The maximum duration of follow-up for
the CBCS phase 1 cases was 11.2 years
(minimum of 8.1 years). During this pe-
riod of observation, the study patients
had 73% overall survival (232 deaths
among 861 cases). Of the 232 deaths,
170 were considered breast cancer-
specific, giving an overall disease-
specific survival of 80% (691 of 861). Af-
rican American cases had worse breast
cancer-specific survival (74%) com-
pared with non–African American cases
(84%) (P.001). Age, race, meno-
pausal status, stage, ER status, PR sta-
tus, TP53 mutation status, mitotic in-
dex, nuclear grade, and histologic grade
were also significant predictors of breast
cancer-specific survival (P.001 for
each).
The breast cancer subtypes also dif-
fered significantly in breast cancer-
specific survival (P.001): basal-like
subtype (75%), HER2/ER− subtype
(52%), luminal A (84%), luminal B
(87%), and unclassified (77%). Kaplan-
Meier survival curves for breast cancer-
specific survival are presented in
FIGURE 2. A steep fall in breast cancer–
specific survival was observed in the
first 4 to 5 years for the basal-like and
HER2/ER− tumors, with particu-
larly poor survival for the HER2/
ER− subtype. A similar early relapse pat-
tern has been described for BRCA1
tumors.44,45 Over the entire observa-
tion period, breast cancer–specific sur-
vival was significantly worse among
basal-like (hazard ratio, 1.8; 95% CI,
1.1-2.9;P=.03) and HER2/ER− breast
cancer patients (hazard ratio, 3.5; 95%
CI, 1.9-6.2; P.001) compared with lu-
minal A as the referent group.
The difference in survival by breast
cancer subtype was seen both among
lymph node–positive patients (P=.01)
and lymph node–negative patients
(P=.03). Data were sparse after strati-
fying on lymph node status and should
be interpreted with caution. Breast can-
cer–specific survival within lymph no-
de–positive patients by subtype was the
following: basal-like (51%), HER2/
ER− (39%), luminal A (65%), luminal
B (83%), and unclassified (44%).
Within the lymph node−negative pa-
tients, breast cancer-specific survival
was the following: basal-like (93%),
HER2/ER− (71%), luminal A (94%),
luminal B (92%), and unclassified
(91%).
The outcomes in premenopausal Af-
rican American cases did not become
more similar to the other groups when
basal-like cases were removed. The
breast cancer−specific survival by ra-
cial and menopausal subsets without
basal-like breast cancers still differed
significantly: premenopausal African
American 64%, postmenopausal Afri-
can American 81%, premenopausal
non–African American 81%, and post-
menopausal non–African American
91% (P.001). These data suggest that
factors other than subtype, such as ac-
cess to treatment, could also be influ-
encing survival in younger African
American women.
COMMENT
Gene expression profiling has identi-
fied breast cancer intrinsic subtypes that
predict distinct clinical outcomes14,15
and which have been shown to be pres-
ent in women of multiple ethnici-
ties.46 The basal-like subtype has been
associated with poor clinical out-
comes,15,16 which likely reflect this sub-
type’s high proliferative capacity14-16 as
well as the lack of directed therapies
since basal-like tumors do not typi-
cally express ER− or overexpress
HER2.17 To facilitate investigation of the
population-based frequencies of the
basal-like breast cancer subtype, we re-
fined an IHC-based assay to identify the
main breast tumor intrinsic subtypes.
We used the IHC method for catego-
rization and determined for the first
time the population-based prevalence
of these subtypes. Although IHC-
based assays do not provide as much
biological insight into tumor biology as
Figure 2. Survival Analysis of the Carolina Breast Cancer Study Cases Grouped Using the
Refined Breast Tumor Immunohistochemical Intrinsic Subtypes
P <.001
S
ur
vi
va
l
Basal-like
Luminal B
Luminal A
Unclassified
HER2+/ER–
No. at Risk
89 78 72 71 25Basal-like
76 67 65 63 17Luminal B
245 226 213 197 81Luminal A
30 28 25 23 9Unclassified
30 27 21 20 7HER2+/ER–
0
1.0
0.8
0.6
0.4
0.2
2 4 86 10
Disease-Specific Survival Time, y
Prevalence was luminal A=51%, luminal B=16%, basal-like=20%, HER2/ER−=7%, and unclassified=6%.
mRNA-based assays containing thou-
sands of genes, this IHC assay allowed
classification of tumors into catego-
ries that have demonstrated associa-
tions between intrinsic subtypes and
proliferation rates, overall survival,
TP53 status, and BRCA1 mutation sta-
tus.14,15,17,29,41,42 The reproducible cor-
relations across different studies and
when using different assays (IHC and
DNA microarray expression profiles)
shows that we are tracking common tu-
mor subtypes with similar biologic
characteristics and clinical behaviors
across distinct patient sets. The IHC-
based classification system also allows
analyses of subtypes to be conducted
in patient populations where fresh tis-
sue is not available.
In the population-based CBCS, the
prevalence of the basal-like and lumi-
nal A breast cancer subtypes was
strongly influenced by race and meno-
pausal status; the highest prevalence of
basal-like and lowest prevalence of lu-
minal A tumors were observed among
premenopausal African American breast
cancer patients. Because the CBCS is a
population-based sample, within de-
fined race and age groups estimates of
prevalence are likely to be representa-
tive of the underlying North Carolina
population.2 Differences between the
CBCS and breast cancer patients re-
ported to the North Carolina Central
Cancer Registry include a lower pro-
portion of African American women be-
tween the ages of 40 and 59 years with
higher-stage tumors and lower partici-
pation among women from lower so-
cioeconomic and educational strata.2,23
Each of these factors could actually pro-
duce an underestimate of the preva-
lence of more aggressive breast cancer
subtypes (basal-like and HER2/
ER−) among younger African Ameri-
can cases enrolled in the CBCS. How-
ever, this potential bias may have been
partially offset by the fact that the analy-
sis of IHC markers in the CBCS was
based on patients with larger tumors.
A high frequency of basal-like tu-
mors was observed in a study of breast
cancer in Nigerian women, among
whom ER-negative and HER2-nega-
tive tumors comprised 87 of 148 women,
or 59% of total cases.47 According to gene
expression studies, ER-negative breast
tumors fall into 1 of 2 categories,14,15
namely basal-like tumors (ER−, PR−, and
HER−) and the HER2/ER− subtype
(HER2/ER−) (Figure 1). The HER2/
ER– group, which is also a high-grade
and ER-negative tumor group, did not
vary significantly with age or race. These
findings suggest that associations be-
tween premenopausal breast cancer,
race, and hormone status in the CBCS
was driven by an excess of the basal-
like subtype. Breast cancers that de-
velop among BRCA1 mutation carriers
are generally basal-like.15,41,42 However,
very few BRCA1mutation carriers were
present in the CBCS, with 2 out of the
4 known carriers falling into the basal-
like category. No BRCA1 carriers were
identified among the African American
cases tested in the CBCS and only a
single variant of unknown biological sig-
nificance was identified.31 Thus BRCA1
variants are unlikely to explain the high
prevalence of basal-like breast cancer in
younger African American patients in
this study.
Basal-like breast cancers in the CBCS
exhibited aggressive features, includ-
ing high proliferative capacity (mea-
sured by mitotic index), high histo-
logic grade, high nuclear grade, and
frequentTP53mutations. Even after ad-
justment for age, race, and stage, the as-
sociation of basal-like and HER2/
ER− subtypes with aggressive features
remained significant. These findings
were expected given the high expres-
sion of the proliferation cluster of genes
in microarray analyses of basal-like and
HER2/ER− subtype tumors.13-15,48 The
association of race with high-grade
breast tumors and ER negativity has
been previously reported.2,3 However,
our study suggests that this associa-
tion is driven by the increased preva-
lence of basal-like tumors and not by
an increase in HER2/ER− subtype.
The observation that the intrinsic
breast cancer subtypes carry different
prognoses was confirmed in the CBCS.
Disease-specific survival was signifi-
cantly lower among breast cancer cases
withbasal-likeandHER2/ER−tumors,
and more favorable among cases with
luminalAtumors.TheHER2/ER−sub-
type appears particularly prone to early
and frequent relapse, befitting the clini-
cal experience with HER2 overexpress-
ingtumors49; theCBCScases inthisstudy
were diagnosed between 1993 and 1996
and were not treated with the anti–
HER2 monoclonal antibody trastu-
zumab. Basal-like tumors were more fre-
quent in younger African American
women in the CBCS, and could contrib-
ute to their poor prognosis compared
with other breast cancer patients. How-
ever, when cases of basal-like tumors
were removed, the breast cancer–
specific survival remained significantly
worse among premenopausal African
Americancases.Asnotedpreviously, this
may reflect the impact on prognosis of
access to care, treatment, or other dif-
ferences. In other words, while the high
incidence of the poor-prognosis basal-
like subtypemaycontribute to their rela-
tivelyworseoutcome, itdoesnotentirely
explain the poor outcomes seen in
younger African Americans. We lacked
treatment data in the CBCS, so we could
not examine interactions between IHC
subtypes and efficacy of cancer therapy.
Examination of tumor microarray data
using patients treated with surgery alone
also suggests that these subtypes are
prognostic and reflect the natural his-
tory of these tumors.15 Interestingly,
unlike HER2/ER− and luminal B
tumors, the basal-like subtype was not
associated with involvement of posi-
tive axillary lymph nodes, a finding that
was previously noted in a study of cyto-
keratin 5/6–positive tumors that over-
sampled BRCA1 tumors.40 Since basal-
like breast cancers still carried a poor
prognosis, it is possible, as suggested by
others,40 that this finding reflects a pre-
dominantly hematogenous, rather than
lymphatic,patternofdissemination.Fur-
ther studies are needed to address this
issue.
Further research is needed to con-
firm the finding that the basal-like
breast tumor subtype shows a high
prevalence in young African Ameri-
can breast cancer patients. In studies of
race and breast cancer, it is important
that race be evaluated in the context of
other variables such as stage at diag-
nosis and tumor histology. Informa-
tion on breast cancer risk factors will
help to determine whether basal-like tu-
mors have a different underlying etiol-
ogy compared with other types of breast
cancer. SinceBRCA1 carriers tend to de-
velop basal-like tumors, there may be
other inherited genetic variants that pre-
dispose to developing specific sub-
types of breast cancer.15,21 The ab-
sence of BRCA1 carriers among African
American breast cancer patients in the
CBCS suggests that genes other than
BRCA1 could predispose women to
basal-like breast cancers; however, en-
vironmental and socioeconomic fac-
tors could also play a role in the ob-
served distribution of breast cancer
subtypes. Notably, in the CBCS, the
prevalence of BRCA1 mutations was 0
in African Americans and low (3.3%)
in non–African Americans.31 Most im-
portantly, our data suggest that epide-
miological studies of breast cancer in
African American women should con-
sider the joint distribution of ER, PR,
and HER2 status (ie, subtypes), rather
than rely on ER and PR status alone.
Previous analyses typically group to-
gether HER2/ER− tumors with basal-
like tumors under the ER-negative des-
ignation; however, in the CBCS,
HER2/ER− tumors were not associ-
ated with race or menopausal status.
The high prevalence of basal-like tu-
mors in younger African American
women could contribute to their higher
breast cancer mortality. Additional
studies of long-term survival among pa-
tients with specific breast cancer sub-
types are needed. Clinical trials aimed
at identifying therapeutic approaches
to the management of basal-like breast
cancer are also needed, especially for
young African American women.
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